Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.48 |
| ▸ | CDK7 | P50613 | 9/20 | 0.44 |
| ▸ | CCNH | P51946 | 9/20 | 0.44 |
| ▸ | MNAT1 | P51948 | 9/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | ITK | Q08881 | 4/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26696916 | 1.00 | EGFR (0.48) | EGFRCDK7CCNHMNAT1CSNK2A1 | |
| SCHEMBL30716328 | 0.84 | EGFR (0.49) | EGFRCDK7CCNHMNAT1CSNK2A1 | |
| SCHEMBL26696830 | 0.84 | EGFR (0.49) | EGFRCDK7CCNHMNAT1CSNK2A1 | |
| SCHEMBL30716324 | 0.82 | EGFR (0.52) | EGFRCDK7CCNHMNAT1BTK | |
| SCHEMBL19918771 | 0.82 | CDK2 (0.43) | CDK7CCNHMNAT1CSNK2A1CDK2 | |
| SCHEMBL30716274 | 0.81 | CDK2 (0.45) | CDK7CCNHCSNK2A1CDK2CDK9 | |
| SCHEMBL21473006 | 0.80 | EGFR (0.45) | EGFRCDK7CCNHMNAT1CSNK2A1 | |
| SCHEMBL18072717 | 0.79 | CDK2 (0.41) | EGFRCDK2CDK9 | |
| SCHEMBL21654892 | 0.78 | CDK7 (0.56) | EGFRCDK7CCNHMNAT1CSNK2A1 | |
| SCHEMBL18113858 | 0.75 | CSNK2A1 (0.53) | CDK7CCNHMNAT1CSNK2A1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023227125-A1 | NEW FUSED-HETEROCYCLIC COMPOUND AS CDK INHIBITOR AND USE THEREOF | 杭州德睿智药科技有限公司 | 2023-11-30 | — | — | WO | disclosed |